Jazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and aggressive form of brain cancer affecting children and young adults. An FDA decision for the molecule, dordaviprone, is expected in August.
Jazz Pharmaceuticals is paying Zymeworks $50 million up front for rights to develop zanidatamab, a bispecific antibody cancer drug currently in two pivotal clinical trials. It’s the second bispecific antibody pact of the week, following Gilead Sciences’ deal to secure an option on a MacroGenics drug in early clinical development.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a drug candidate that expands the company’s scope to immuno-oncology.
The deal struck Thursday follows similar settlements between the Department of Justice and three other drugmakers. The department alleged that the companies started copay-assistance funds that violated anti-kickback laws.
The drug offers greater convenience and efficacy than the old chemotherapy combination, but its high cost and first impressions among doctors may explain why Jazz had to lower its sales guidance.
Also, the College of Healthcare Information Executives has created the CHIME Cybersecurity Center and Program Office, and ProofPilot CEO talks about the challenge of balancing digital health startup investor expectations with those of customers.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.